Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In With The Old? 2013 To Mark Rebirth Of CDER’s Pharmacy Compounding, Medical Imaging AdComms

Executive Summary

FDA has signaled that it will re-form its Pharmacy Compounding Drugs Advisory Committee, which was dissolved in 2002, as it deals with an ongoing meningitis outbreak related to compounded steroid injections. 2012 proved to be another busy year for the Oncologic Drugs Advisory Committee, but the full drug safety/risk management panel saw a significantly lighter workload than in recent years.

You may also be interested in...



FDA Says Goodbye To Its Antiviral Drugs Advisory Committee

Agency terminates the panel, which has not met since October 2013, after finding it was “no longer needed.” The committee’s activities will be taken up by the anti-infective drugs panel, which has been renamed the Antimicrobial Drugs Advisory Committee.

CDER Advisory Committee Staffing Improves, But Trouble Spots Remain

After years of widespread vacancies on advisory committees, the Food & Drug Administration appears to have tackled most of the problems. But there are a couple of significant outliers, most significantly the Dermatology & Ophthalmic Products Advisory Committee. Will changes in conflict of interest rules and a new recruitment effort help FDA find and retain advisory committee members?

NME Sponsors Followed PDUFA V’s “Program” To Advisory Committee Success In 2013

New review model’s elements, including the mid-cycle communication and late-cycle meeting, helped make for a smoother advisory committee process for Janssen’s Olysio and Bayer’s Adempas. The sponsors and FDA review staff were able to reach agreement on labeling and other review issues in advance, narrowing the scope of matters requiring vetting by the expert panels.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel